All In Biotech

Drug Trial Radar · NCT04214288

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

240

Actual

Start

Apr 22, 2020

Primary completion

Aug 30, 2022

Study completion Jun 16, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.

Conditions

  • Advanced ER-Positive HER2-Negative Breast Cancer

Interventions

  • AZD9833Drug

    Dosage formulation: AZD9833 tablets will be administered orally.

  • FulvestrantDrug

    Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: From date of randomisation to date of objective disease progression (or last evaluable assessment in the absence of progression) or death (up to data cut-off of 29 months)

Locations

85 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Long Beach, California

  • Research Site

    Fort Myers, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Canton, Ohio

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Eagle River, Wisconsin

  • Research Site

    Brasschaat, Belgium

  • Research Site

    Charleroi, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Haine-Saint-Paul, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Libramont-Chevigny, Belgium

  • Research Site

    Namur, Belgium

  • Research Site

    Greenfield Park, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Paris, France

  • Research Site

    Vandœuvre-lès-Nancy, France

  • Research Site

    Batumi, Georgia

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Berlin, Germany

  • Research Site

    Düsseldorf, Germany

  • Research Site

    Essen, Germany

  • Research Site

    Budapest, Hungary

  • Research Site

    Debrecen, Hungary

  • Research Site

    Kaposvár, Hungary

  • Research Site

    Kecskemét, Hungary

  • Research Site

    Nyíregyháza, Hungary

  • Research Site

    Pécs, Hungary

  • Research Site

    Szeged, Hungary

  • Research Site

    Jerusalem, Israel

  • Research Site

    Jerusalem, Israel

  • Research Site

    Nahariya, Israel

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.